Dr Kiran Mazumdar-Shaw, CMD, Biocon
Here is an exclusive from Syngene and Baxter's management to BioSpectrum:
How much of investment went in to erecting the BGRC?
Dr Kiran Mazumdar-Shaw, CMD, Biocon: Syngene has invested for building the whole infrastructure.
There has been a significant capital investment, and we are also building a stability center in our campus.
Can you tell us something about this collaboration?